$SSII SS Innovations to Uplist to Nasdaq https:
Post# of 25561
(Total Views: 98)
Posted On: 04/24/2025 9:42:58 AM
$SSII SS Innovations to Uplist to Nasdaq
https://www.globenewswire.com/news-release/20...asdaq.html
FORT LAUDERDALE, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that the Company’s common stock has been approved for listing on The Nasdaq Capital Market® (“Nasdaq”). Trading on Nasdaq is expected to commence on April 25, 2025, and the Company’s shares will continue to be listed under the ticker symbol “SSII”.
Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “Uplisting to Nasdaq marks an exciting milestone for SS Innovations and reflects our team’s achievements in building a world-class robotic surgery technology platform that is designed to offer top-tier quality, safety, efficiency and affordability, enabling cutting-edge robotic surgical procedures for a wider range of patients globally.
“The timing of our uplisting coincides with the beginning of our global expansion beyond India – into Nepal, Ecuador, Guatemala, the Philippines, Indonesia, Sri Lanka and Ukraine – and our planned strategic entry into Europe and the United States. We are pursuing EU CE Mark and U.S. FDA approval for our SSi Mantra surgical robotic system, which we anticipate in late 2025 and early 2026, respectively. We believe that the Nasdaq uplisting will enhance market awareness of our growth story, improve transparency, expand our audience of potential investors, and ultimately increase share liquidity.”
Dr. Srivastava also highlighted the Company’s recent achievements in advancing its clinically validated, patented surgical robotic system, the “SSi Mantra,” including:
Installing 80 SSi Mantra systems in 75 hospitals across India and other countries;
3,500+ surgeries performed using the SSi Mantra, including over 195 robotic cardiac surgeries with zero reported device-related mortality, injuries, or complications;
Becoming the first and only company in India to receive Central Drugs Standard Control Organization (CDSCO, India’s equivalent of the U.S. FDA) regulatory approval for use of a robotic surgical system in the performance of telesurgery and tele-proctoring procedures. Since receiving such approvals, the Company has performed 16 telesurgeries using SSi Mantra, including the world’s first robotic cardiac telesurgeries over distances up to 1,200 miles; and
Reporting revenue for the year ended December 31, 2024 of $20.6 million, an approximately 251% increase from 2023 revenue of $5.9 million, and gross margin of 40.9%, an increase from 12.3% in 2023.
https://www.globenewswire.com/news-release/20...asdaq.html
FORT LAUDERDALE, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that the Company’s common stock has been approved for listing on The Nasdaq Capital Market® (“Nasdaq”). Trading on Nasdaq is expected to commence on April 25, 2025, and the Company’s shares will continue to be listed under the ticker symbol “SSII”.
Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “Uplisting to Nasdaq marks an exciting milestone for SS Innovations and reflects our team’s achievements in building a world-class robotic surgery technology platform that is designed to offer top-tier quality, safety, efficiency and affordability, enabling cutting-edge robotic surgical procedures for a wider range of patients globally.
“The timing of our uplisting coincides with the beginning of our global expansion beyond India – into Nepal, Ecuador, Guatemala, the Philippines, Indonesia, Sri Lanka and Ukraine – and our planned strategic entry into Europe and the United States. We are pursuing EU CE Mark and U.S. FDA approval for our SSi Mantra surgical robotic system, which we anticipate in late 2025 and early 2026, respectively. We believe that the Nasdaq uplisting will enhance market awareness of our growth story, improve transparency, expand our audience of potential investors, and ultimately increase share liquidity.”
Dr. Srivastava also highlighted the Company’s recent achievements in advancing its clinically validated, patented surgical robotic system, the “SSi Mantra,” including:
Installing 80 SSi Mantra systems in 75 hospitals across India and other countries;
3,500+ surgeries performed using the SSi Mantra, including over 195 robotic cardiac surgeries with zero reported device-related mortality, injuries, or complications;
Becoming the first and only company in India to receive Central Drugs Standard Control Organization (CDSCO, India’s equivalent of the U.S. FDA) regulatory approval for use of a robotic surgical system in the performance of telesurgery and tele-proctoring procedures. Since receiving such approvals, the Company has performed 16 telesurgeries using SSi Mantra, including the world’s first robotic cardiac telesurgeries over distances up to 1,200 miles; and
Reporting revenue for the year ended December 31, 2024 of $20.6 million, an approximately 251% increase from 2023 revenue of $5.9 million, and gross margin of 40.9%, an increase from 12.3% in 2023.
(0)
(0)